Givaudan continues to invest in its Active Beauty business unit and its metagenomics platform to boost its pioneering position in the microbiome market. Givaudan, which claims to be the only fragrance company with in-house microbiome research capabilities, says these new strategic investments will help the company to remain one of the leaders in the development of new actives focusing on the skin microbiome.
The company recently equipped its Applied Microbiomics Centre of Excellence in Toulouse, France, with a state-of-the-art automation equipment allowing high throughput screenings (HTS). This should accelerate the development of more disruptive solutions to activate, protect or balance the skin microbiota.
“Our astonishing advancements in microbiomics allow us to bring ground-breaking cosmetic concepts to new and existing customers. As the microbiome trend continues to grow, our teams will be at the forefront of this exciting area of scientific research,” said Laurent Bourdeau, Head of Active Beauty.
Givaudan’s first discoveries in this field - such as microbiome activated’ ingredients as well as ’microbiome protecting’ agents - have resulted in the development of two award-winning active cosmetic ingredients, Brightenyl and Revivyl.
Brightenyl, the first microbiome activated skin brightener, won a Gold and Bronze Innovation Award in 2015 at in-cosmetics Global and in-cosmetics Latin America, respectively. The first holistic skin renewal accelerator, Revivyl, won Gold for Best Innovation Award at in-cosmetics Latin America and in-cosmetics Asia in 2017.
“It’s incredibly fascinating for a fragrance house to lead the creation of new active cosmetic ingredients in microbiomics. I’m very proud of the team in our Applied Microbiomics Centre of Excellence which is constantly pioneering the ingredients of tomorrow. This also includes our teams around the world working alongside our customers to create inventive new products for their markets,” concluded Maurizio Volpi, President of Givaudan’s Fragrance Division.